TitleEffects of hypothalamic leptin gene therapy on osteopetrosis in leptin-deficient mice.
Publication TypeJournal Article
Year of Publication2018
AuthorsPhilbrick, KA, Martin, SA, Colagiovanni, AR, Branscum, AJ, Turner, RT, Iwaniec, UT
JournalJ Endocrinol
Volume236
Issue2
Pagination57-68
Date Published02/2018
ISSN1479-6805
KeywordsAnimals, Bone Density, Genetic Therapy, Hypothalamus, Leptin, Male, Mice, Mice, Inbred C57BL, Mice, Obese, Mice, Transgenic, Obesity, Osteoclasts, Osteopetrosis
Abstract
 

Impaired resorption of cartilage matrix deposited during endochondral ossification is a defining feature of juvenile osteopetrosis. Growing, leptin-deficient mice exhibit a mild form of osteopetrosis. However, the extent to which the disease is (1) self-limiting and (2) reversible by leptin treatment is unknown. We addressed the first question by performing histomorphometric analysis of femurs in rapidly growing (2-month-old), slowly growing (4-month-old) and skeletally mature (6-month-old) wild-type (WT) and male mice. Absent by 6 months of age in WT mice, cartilage matrix persisted to varying extents in distal femur epiphysis, metaphysis and diaphysis in mice, suggesting that the osteopetrotic phenotype is not entirely self-limiting. To address the second question, we employed hypothalamic recombinant adeno-associated virus (rAAV) gene therapy to restore leptin signaling in mice. Two-month-old mice were randomized to one of the three groups: (1) untreated control, (2) rAAV-Leptin or (3) control vector rAAV-green fluorescent protein and vectors injected intracerebroventricularly. Seven months later, rAAV-leptin-treated mice exhibited no cartilage in the metaphysis and greatly reduced cartilage in the epiphysis and diaphysis. At the cellular level, the reduction in cartilage was associated with increased bone turnover. These findings (1) support the concept that leptin is important for normal replacement of cartilage by bone, and (2) demonstrate that osteopetrosis in mice is bone-compartment-specific and reversible by leptin at skeletal sites capable of undergoing robust bone turnover.

DOI10.1530/JOE-17-0524
Alternate JournalJ. Endocrinol.
PubMed ID29191939
PubMed Central IDPMC5771473
Grant ListR01 AR060913 / AR / NIAMS NIH HHS / United States
R03 AR054609 / AR / NIAMS NIH HHS / United States